NASDAQ:LNTH - Lantheus Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $24.73 +0.41 (+1.69 %) (As of 05/26/2019 06:09 AM ET)Previous Close$24.73Today's Range$24.18 - $24.7952-Week Range$12.59 - $26.40Volume870,895 shsAverage Volume329,065 shsMarket Capitalization$960.02 millionP/E Ratio26.31Dividend YieldN/ABeta1.52 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neurolite, an injectable to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures to assess blood flow to the muscle of the heart; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Cobalt (Co 57), a non-pharmaceutical radiochemical used in the manufacture of sources for the calibration and maintenance of single-photon emission computed tomography imaging cameras. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201, which is used in MPI studies to detect cardiovascular disease; Gallium Ga 67 that is used to detect various infections and cancerous tumors; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; and LMI 1195 that is in Phase III clinical trials for the diagnosis and treatment follow-up of neuroendocrine tumors. The company sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics, and group practices. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts. Receive LNTH News and Ratings via Email Sign-up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LNTH Previous Symbol CUSIPN/A CIK1521036 Webhttp://www.lantheus.com/ Phone978-671-8001Debt Debt-to-Equity Ratio3.16 Current Ratio4.57 Quick Ratio3.82Price-To-Earnings Trailing P/E Ratio26.31 Forward P/E Ratio22.28 P/E Growth1.86 Sales & Book Value Annual Sales$343.37 million Price / Sales2.80 Cash Flow$1.3625 per share Price / Cash Flow18.15 Book Value$2.14 per share Price / Book11.56Profitability EPS (Most Recent Fiscal Year)$0.94 Net Income$40.51 million Net Margins12.17% Return on Equity59.57% Return on Assets8.85%Miscellaneous Employees488 Outstanding Shares38,820,000Market Cap$960.02 million Next Earnings Date8/7/2019 (Estimated) OptionableOptionable Lantheus (NASDAQ:LNTH) Frequently Asked Questions What is Lantheus' stock symbol? Lantheus trades on the NASDAQ under the ticker symbol "LNTH." How were Lantheus' earnings last quarter? Lantheus Holdings Inc (NASDAQ:LNTH) posted its quarterly earnings data on Tuesday, April, 30th. The medical equipment provider reported $0.28 EPS for the quarter, beating the Zacks' consensus estimate of $0.25 by $0.03. The medical equipment provider earned $86.51 million during the quarter, compared to the consensus estimate of $86.80 million. Lantheus had a net margin of 12.17% and a return on equity of 59.57%. View Lantheus' Earnings History. When is Lantheus' next earnings date? Lantheus is scheduled to release their next quarterly earnings announcement on Wednesday, August 7th 2019. View Earnings Estimates for Lantheus. What guidance has Lantheus issued on next quarter's earnings? Lantheus issued an update on its FY 2019 earnings guidance on Tuesday, April, 30th. The company provided EPS guidance of $1.14-1.17 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.16. The company issued revenue guidance of $357.967-363.118 million, compared to the consensus revenue estimate of $360.74 million.Lantheus also updated its Q2 2019 guidance to $0.23-0.28 EPS. What price target have analysts set for LNTH? 2 equities research analysts have issued 12-month price targets for Lantheus' stock. Their forecasts range from $20.00 to $21.00. On average, they anticipate Lantheus' stock price to reach $20.50 in the next year. This suggests that the stock has a possible downside of 17.1%. View Analyst Price Targets for Lantheus. What is the consensus analysts' recommendation for Lantheus? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus. Has Lantheus been receiving favorable news coverage? News stories about LNTH stock have been trending positive on Sunday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Lantheus earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned news stories about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days. Who are some of Lantheus' key competitors? Some companies that are related to Lantheus include Neogen (NEOG), Immunomedics (IMMU), Quidel (QDEL), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Quotient (QTNT), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX) and ImmuCell (ICCC). What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include Mobileye (MBBYF), CBL & Associates Properties (CBL), Gerdau (GGB), Energy Transfer LP Unit (ET), Cypress Semiconductor (CY), Ares Capital (ARCC), Anavex Life Sciences (AVXL), Exelixis (EXEL), Amicus Therapeutics (FOLD) and Frontier Communications (FTR). Who are Lantheus' key executives? Lantheus' management team includes the folowing people: Ms. Mary Anne Heino, CEO, Pres & Director (Age 59)Mr. Robert J. Marshall Jr., CFO & Treasurer (Age 52)Mr. Michael P. Duffy, Sr. VP of Law & Public Policy, Gen. Counsel and Sec. (Age 58)Dr. Cesare Orlandi, Chief Medical Officer (Age 69)Mr. John J. Bolla, Chief Operating Officer (Age 49) When did Lantheus IPO? (LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager. Who are Lantheus' major shareholders? Lantheus' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.50%), Wellington Management Group LLP (4.27%), LSV Asset Management (4.21%), Vaughan Nelson Investment Management L.P. (4.09%), Dimensional Fund Advisors LP (3.79%) and Renaissance Technologies LLC (3.70%). Company insiders that own Lantheus stock include A Frederick Robertson, Avista Capital Partners Gp, Ll, Brian A Markison, Cesare Orlandi, David F Burgstahler, Derace L Schaffer, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy and Timothy G Healey. View Institutional Ownership Trends for Lantheus. Which institutional investors are selling Lantheus stock? LNTH stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Wells Fargo & Company MN, Morgan Stanley, AlphaOne Investment Services LLC, Gabelli Funds LLC, Citigroup Inc., Royce & Associates LP and Peregrine Capital Management LLC. Company insiders that have sold Lantheus company stock in the last year include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, Julie Mchugh, Mary Anne Heino and Michael P Duffy. View Insider Buying and Selling for Lantheus. Which institutional investors are buying Lantheus stock? LNTH stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, SG Americas Securities LLC, JPMorgan Chase & Co., Oxford Asset Management LLP, CIBC World Markets Inc., Dimensional Fund Advisors LP, BlackRock Inc. and Vaughan Nelson Investment Management L.P.. View Insider Buying and Selling for Lantheus. How do I buy shares of Lantheus? Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Lantheus' stock price today? One share of LNTH stock can currently be purchased for approximately $24.73. How big of a company is Lantheus? Lantheus has a market capitalization of $960.02 million and generates $343.37 million in revenue each year. The medical equipment provider earns $40.51 million in net income (profit) each year or $0.94 on an earnings per share basis. Lantheus employs 488 workers across the globe. What is Lantheus' official website? The official website for Lantheus is http://www.lantheus.com/. How can I contact Lantheus? Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected] MarketBeat Community Rating for Lantheus (NASDAQ LNTH)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 228 (Vote Outperform)Underperform Votes: 204 (Vote Underperform)Total Votes: 432MarketBeat's community ratings are surveys of what our community members think about Lantheus and other stocks. Vote "Outperform" if you believe LNTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LNTH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: Convertible Shares Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.